Silence at Takeda and Nycomed, but a desire to expand
This article was originally published in Scrip
Takeda and Nycomed have both refused to comment on the rumoured acquisition discussions. Japan's largest drug firm is said to be considering paying up to $14 billion for the Swiss pharma company, whose largest shareholder is Nordic Capital with around a 42% stake. However, advisors close to the companies have indicated that there is substance to the rumour.
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.